首页 > 最新文献

Journal of carcinogenesis & mutagenesis最新文献

英文 中文
Relationships between gut microbiota, red meat consumption and colorectal cancer. 肠道微生物群、食用红肉与结肠直肠癌之间的关系。
Pub Date : 2022-01-01 Epub Date: 2022-05-12
Mahamane Talphi Diakité, Bréhima Diakité, Amadou Koné, Saidou Balam, Djeneba Fofana, Dramane Diallo, Yaya Kassogué, Cheick B Traoré, Bakarou Kamaté, Djibril Ba, Madani Ly, Mamadou Ba, Bourahima Koné, Almoustapha I Maiga, Chad Achenbach, Jane Holl, Robert Murphy, Lifang Hou, Mamoudou Maiga

Excessive consumption of red and processed meat has been associated with a higher risk of developing colorectal cancer. There are many attempts to explain the risk of colorectal cancer associated with the consumption of red and processed meat: The temperature cooking of meat such as grilling and smoking contribute to the formation of mutagenic compounds including heterocyclic amines and polycyclic aromatic hydrocarbons.Heme iron in red meat is involved in the formation of N-nitroso compounds and lipid peroxidation products in the digestive tract.Fatty red meat is involved in the production of secondary bile acids by the bacteria of the gut microbiota. Many of the products formed are genotoxic and can cause DNA damage and initiate carcinogenesis of colorectal cancer. Various mechanisms contributing to their genotoxic role have been established in human and animal studies. In addition, there is increasing evidence that compounds formed from red and processed meat interact with the gut microbiota in colorectal cancer pathways. Although several early studies in animals and humans suggest a direct causal role of the gut microbiota in the development of colorectal cancer, the links between diet, gut microbiota, and colonic carcinogenesis are largely associations rather than proven causal relationships. Various biological mechanisms, including inflammation and oxidative stress can lead to DNA damage, gut dysbiosis, and therefore increase the risk of colorectal cancer. Dysbiosis of the gut microbiota may increase the risk of colorectal cancer through dietary component promotion of colonic carcinogenesis. In this paper, we review and update current knowledge about the relationships between red meat consumption, gut microbiota, and colorectal cancer.

过量食用红肉和加工肉类与罹患大肠癌的风险较高有关。有许多人试图解释与食用红肉和加工肉类有关的大肠癌风险:红肉中的血红素铁参与了 N-亚硝基化合物和脂质过氧化产物在消化道中的形成。形成的许多产物都具有基因毒性,可导致 DNA 损伤并引发结肠直肠癌的发生。在人类和动物研究中已确定了导致其基因毒性作用的各种机制。此外,越来越多的证据表明,红肉和加工肉类形成的化合物与肠道微生物群在大肠癌的发病途径中相互作用。尽管一些早期的动物和人体研究表明,肠道微生物群在结直肠癌的发生中起着直接的因果作用,但饮食、肠道微生物群和结肠癌发生之间的联系在很大程度上是关联关系,而不是已被证实的因果关系。包括炎症和氧化应激在内的各种生物机制可导致 DNA 损伤、肠道菌群失调,从而增加罹患结直肠癌的风险。肠道微生物群失调可能会通过膳食成分促进结肠癌的发生,从而增加患结直肠癌的风险。在本文中,我们回顾并更新了当前有关红肉消费、肠道微生物群和结直肠癌之间关系的知识。
{"title":"Relationships between gut microbiota, red meat consumption and colorectal cancer.","authors":"Mahamane Talphi Diakité, Bréhima Diakité, Amadou Koné, Saidou Balam, Djeneba Fofana, Dramane Diallo, Yaya Kassogué, Cheick B Traoré, Bakarou Kamaté, Djibril Ba, Madani Ly, Mamadou Ba, Bourahima Koné, Almoustapha I Maiga, Chad Achenbach, Jane Holl, Robert Murphy, Lifang Hou, Mamoudou Maiga","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Excessive consumption of red and processed meat has been associated with a higher risk of developing colorectal cancer. There are many attempts to explain the risk of colorectal cancer associated with the consumption of red and processed meat: The temperature cooking of meat such as grilling and smoking contribute to the formation of mutagenic compounds including heterocyclic amines and polycyclic aromatic hydrocarbons.Heme iron in red meat is involved in the formation of N-nitroso compounds and lipid peroxidation products in the digestive tract.Fatty red meat is involved in the production of secondary bile acids by the bacteria of the gut microbiota. Many of the products formed are genotoxic and can cause DNA damage and initiate carcinogenesis of colorectal cancer. Various mechanisms contributing to their genotoxic role have been established in human and animal studies. In addition, there is increasing evidence that compounds formed from red and processed meat interact with the gut microbiota in colorectal cancer pathways. Although several early studies in animals and humans suggest a direct causal role of the gut microbiota in the development of colorectal cancer, the links between diet, gut microbiota, and colonic carcinogenesis are largely associations rather than proven causal relationships. Various biological mechanisms, including inflammation and oxidative stress can lead to DNA damage, gut dysbiosis, and therefore increase the risk of colorectal cancer. Dysbiosis of the gut microbiota may increase the risk of colorectal cancer through dietary component promotion of colonic carcinogenesis. In this paper, we review and update current knowledge about the relationships between red meat consumption, gut microbiota, and colorectal cancer.</p>","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"13 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9574089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cemento Ossifying Fibroma: A Pathological Entity 骨水泥骨化纤维瘤:一种病理实体
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.12.359
S. MohammadShahid, H. Raj, Anil Raj Ks
Cemento-ossifying fibroma is a controversial term because of its terminology and its diagnosis. Cemento-ossifying fibroma is odontogenic in origin although it is a central neoplasm of bone and involving the periodontium. Most Cemento-ossifying fibromas exhibit slow and expansile growth in the jaws and are benign in origin. The lesion is encapsulated with mixed radiodensties. The Cemento-ossifying fibroma is characterized by replaced of normal bone by fibrous tissue and varying amounts of osteoid and cementum like material. The definitive diagnosis of such lesions require clinical, radiological and histopathological observations. The treatment of choice is surgical resection and recurrence in uncommon. We report a case of Cemento ossifying fibroma in left mandibular premolar region and discuss how to confirm the diagnosis.
骨水泥骨化纤维瘤是一个有争议的术语,因为它的术语和诊断。骨水泥骨化纤维瘤起源于牙源性,虽然它是骨的中心肿瘤并累及牙周组织。大多数骨水泥骨化纤维瘤在颌骨中表现出缓慢而扩张的生长,并且起源于良性。病变被混合放射密度包裹。骨水泥骨化纤维瘤的特征是正常骨被纤维组织和不同数量的类骨和骨水泥样物质所取代。这种病变的明确诊断需要临床、放射学和组织病理学观察。治疗选择手术切除,复发少见。我们报告1例左下颌前磨牙骨水泥骨化纤维瘤,并讨论如何确诊。
{"title":"Cemento Ossifying Fibroma: A Pathological Entity","authors":"S. MohammadShahid, H. Raj, Anil Raj Ks","doi":"10.35248/2157-2518.21.12.359","DOIUrl":"https://doi.org/10.35248/2157-2518.21.12.359","url":null,"abstract":"Cemento-ossifying fibroma is a controversial term because of its terminology and its diagnosis. Cemento-ossifying fibroma is odontogenic in origin although it is a central neoplasm of bone and involving the periodontium. Most Cemento-ossifying fibromas exhibit slow and expansile growth in the jaws and are benign in origin. The lesion is encapsulated with mixed radiodensties. The Cemento-ossifying fibroma is characterized by replaced of normal bone by fibrous tissue and varying amounts of osteoid and cementum like material. The definitive diagnosis of such lesions require clinical, radiological and histopathological observations. The treatment of choice is surgical resection and recurrence in uncommon. We report a case of Cemento ossifying fibroma in left mandibular premolar region and discuss how to confirm the diagnosis.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"99 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86365066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Does the Absence of Down-Regulation of MHC-I in Cancer Cells Necessarily Lead to their Annihilation by Immunologic Attack? 肿瘤细胞中mhc - 1下调缺失是否必然导致其被免疫攻击消灭?
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.S6.001
P. Sinha
It has long been known now that MHC-I is down-regulated in several cancers and this has been linked with impaired immune attack against cancer cells. It is obvious then that low MHC-I expression is also linked with poor survival of cancer patients. But, however, through a careful analysis of the prognostic influence of MHC-I expression in colorectal cancer, head and neck squamous cell carcinoma, and biliary tract cancer, I conclude that the percentage of deaths of patients with high MHC-I expression in tumor (due to tumor alone) out of the total number of deaths (due to tumor alone) is not insignificant when compared to the percentage of deaths of cancer patients with low MHC-I expression in tumor. Hence the absence of down-regulation of MHC-I in cancer cells does not necessarily lead to their annihilation by immunologic attack. Stated differently, the down-regulation of MHC-I in cancer cells is not a necessary step in the genesis of cancer. New research needs to be directed at finding the immune evasion mechanism in cancer cells with high MHC-I expression. I finish the paper by speculating on few such mechanisms. Two of the important mechanisms speculated are clonal deletion of T cells (in the thymus) directed against antigens on Cancer Stem Cells, and down-regulation of MHC-II in metastatic cells which arise possibly by the fusion of hematopoietic stem cells and their lineages with tumor cells
人们早就知道,mhc - 1在几种癌症中下调,这与对癌细胞的免疫攻击受损有关。很明显,低mhc - 1表达也与癌症患者的低生存率有关。但是,通过仔细分析MHC-I在结直肠癌、头颈鳞状细胞癌和胆道癌中的表达对预后的影响,我得出结论,与肿瘤中MHC-I低表达的癌症患者的死亡率相比,肿瘤中MHC-I高表达的患者(仅因肿瘤)的死亡人数占总死亡人数的比例并非微不足道。因此,癌细胞中mhc - 1下调的缺失并不一定会导致它们被免疫攻击所消灭。换句话说,癌细胞中mhc - 1的下调并不是癌症发生的必要步骤。新的研究需要针对高MHC-I表达的癌细胞寻找免疫逃避机制。最后,我对几个这样的机制进行了推测。推测的两个重要机制是针对肿瘤干细胞抗原的T细胞克隆性缺失(在胸腺中)和转移细胞中MHC-II的下调,这可能是由于造血干细胞及其谱系与肿瘤细胞融合而产生的
{"title":"Does the Absence of Down-Regulation of MHC-I in Cancer Cells Necessarily Lead to their Annihilation by Immunologic Attack?","authors":"P. Sinha","doi":"10.35248/2157-2518.21.S6.001","DOIUrl":"https://doi.org/10.35248/2157-2518.21.S6.001","url":null,"abstract":"It has long been known now that MHC-I is down-regulated in several cancers and this has been linked with impaired immune attack against cancer cells. It is obvious then that low MHC-I expression is also linked with poor survival of cancer patients. But, however, through a careful analysis of the prognostic influence of MHC-I expression in colorectal cancer, head and neck squamous cell carcinoma, and biliary tract cancer, I conclude that the percentage of deaths of patients with high MHC-I expression in tumor (due to tumor alone) out of the total number of deaths (due to tumor alone) is not insignificant when compared to the percentage of deaths of cancer patients with low MHC-I expression in tumor. Hence the absence of down-regulation of MHC-I in cancer cells does not necessarily lead to their annihilation by immunologic attack. Stated differently, the down-regulation of MHC-I in cancer cells is not a necessary step in the genesis of cancer. New research needs to be directed at finding the immune evasion mechanism in cancer cells with high MHC-I expression. I finish the paper by speculating on few such mechanisms. Two of the important mechanisms speculated are clonal deletion of T cells (in the thymus) directed against antigens on Cancer Stem Cells, and down-regulation of MHC-II in metastatic cells which arise possibly by the fusion of hematopoietic stem cells and their lineages with tumor cells","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"13 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79265284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FGF2- Mediated Programming of Macrophages: A Novel Target for Cancer Therapy 巨噬细胞FGF2介导的编程:癌症治疗的新靶点
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.12.362
J. Im, R. Muschel
Macrophages are present in essentially all cancers. In general these Tumor Associated Macrophages (TAMs) facilitate the growth of cancers, suppress the anti-cancer immune response and promote angiogenesis. Because of these tumor promoting actions, targeting macrophages is a promising, but mainly unrealized strategy for cancer therapy.
巨噬细胞基本上存在于所有的癌症中。一般来说,这些肿瘤相关巨噬细胞(Tumor Associated Macrophages, tam)促进肿瘤生长,抑制抗癌免疫反应,促进血管生成。由于这些肿瘤促进作用,靶向巨噬细胞是一种很有前途的癌症治疗策略,但主要尚未实现。
{"title":"FGF2- Mediated Programming of Macrophages: A Novel Target for Cancer Therapy","authors":"J. Im, R. Muschel","doi":"10.35248/2157-2518.21.12.362","DOIUrl":"https://doi.org/10.35248/2157-2518.21.12.362","url":null,"abstract":"Macrophages are present in essentially all cancers. In general these Tumor Associated Macrophages (TAMs) facilitate the growth of cancers, suppress the anti-cancer immune response and promote angiogenesis. Because of these tumor promoting actions, targeting macrophages is a promising, but mainly unrealized strategy for cancer therapy.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"19 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77527981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statistics and Analysis of Cancer Across the World 全球癌症统计与分析
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.S18.E002
Elizabeth Grace
{"title":"Statistics and Analysis of Cancer Across the World","authors":"Elizabeth Grace","doi":"10.35248/2157-2518.21.S18.E002","DOIUrl":"https://doi.org/10.35248/2157-2518.21.S18.E002","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"8 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82834405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Covid 19 on Cancer Covid - 19对癌症的影响
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.12.E127
J. Maheswari
{"title":"Impact of Covid 19 on Cancer","authors":"J. Maheswari","doi":"10.35248/2157-2518.21.12.E127","DOIUrl":"https://doi.org/10.35248/2157-2518.21.12.E127","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"39 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78410933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison RNA Expression Level of HER2 (By QRT-PCR) With Protein Expression Level (Immunohistochemistry) and Investigation HER 2 Expression Level with Clinicopathological Features HER2 RNA表达水平(QRT-PCR)与蛋白表达水平(免疫组化)的比较,探讨HER2表达水平与临床病理特征的关系
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.S18.003
Samira Shabani, Tayebeh Majidi Zadeh, Ameneh Tavakoli Koudehi, Frouz, E. Mahjoubi
Background: Evaluation HER2 (human epidermal growth factor receptor 2) status is considered as a standard practice in breast cancer clinical management. There are different methods for evaluation HER2 status, but currently the routine method for assessment of HER2 status is Immunohistochemistry (IHC) .The aim of the this study was to compare the results obtained by IHC and Quantitative Real Time PCR methods in determination of HER2 status to specify whether QRT- PCR can use as supplementary method in breast cancer or not. Methods: In this regard, 48 fresh tissues from patients with breast tumor were studied. IHC, qRT- PCR technique was done in every speciman. IHC was done with DAKO HercepTest and QRT- PCR method was performed with TaqMan probes and primers in lightcyclerTMsystem (Corbett Real Time Thermal cycler). Results: No Correlations was seen between relative HER2 mRNA expression and IHC HER2 status. Furthermore, the relation between HER2 expression level and patient's age, tumor size, lymph node involvement and tumor grade was not significant. Conclusion: The present results show that the relative mRNA levels of HER2 by using q RT-PCR cannot discriminate between HER2 IHC positive from negative
背景:评估HER2(人表皮生长因子受体2)状态被认为是乳腺癌临床管理的标准做法。评估HER2状态的方法有很多,目前评估HER2状态的常规方法是免疫组化(Immunohistochemistry, IHC)。本研究的目的是比较免疫组化(Immunohistochemistry, IHC)和实时荧光定量PCR (Quantitative Real Time PCR)检测HER2状态的结果,以明确QRT- PCR是否可以作为乳腺癌检测的辅助方法。方法:对48例乳腺肿瘤患者的新鲜组织进行研究。每个标本均采用免疫组化、qRT- PCR技术。采用DAKO HercepTest进行免疫组化,在lightcyclertm系统(Corbett Real Time Thermal cycler)中使用TaqMan探针和引物进行QRT- PCR检测。结果:HER2 mRNA相对表达量与IHC HER2状态无相关性。此外,HER2表达水平与患者年龄、肿瘤大小、淋巴结受累程度和肿瘤分级之间无显著相关性。结论:目前的结果表明,利用q - RT-PCR检测的HER2相对mRNA水平不能区分HER2 IHC阳性和阴性
{"title":"Comparison RNA Expression Level of HER2 (By QRT-PCR) With Protein Expression Level (Immunohistochemistry) and Investigation HER 2 Expression Level with Clinicopathological Features","authors":"Samira Shabani, Tayebeh Majidi Zadeh, Ameneh Tavakoli Koudehi, Frouz, E. Mahjoubi","doi":"10.35248/2157-2518.21.S18.003","DOIUrl":"https://doi.org/10.35248/2157-2518.21.S18.003","url":null,"abstract":"Background: Evaluation HER2 (human epidermal growth factor receptor 2) status is considered as a standard practice in breast cancer clinical management. There are different methods for evaluation HER2 status, but currently the routine method for assessment of HER2 status is Immunohistochemistry (IHC) .The aim of the this study was to compare the results obtained by IHC and Quantitative Real Time PCR methods in determination of HER2 status to specify whether QRT- PCR can use as supplementary method in breast cancer or not. Methods: In this regard, 48 fresh tissues from patients with breast tumor were studied. IHC, qRT- PCR technique was done in every speciman. IHC was done with DAKO HercepTest and QRT- PCR method was performed with TaqMan probes and primers in lightcyclerTMsystem (Corbett Real Time Thermal cycler). Results: No Correlations was seen between relative HER2 mRNA expression and IHC HER2 status. Furthermore, the relation between HER2 expression level and patient's age, tumor size, lymph node involvement and tumor grade was not significant. Conclusion: The present results show that the relative mRNA levels of HER2 by using q RT-PCR cannot discriminate between HER2 IHC positive from negative","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80496628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimally Invasive Distal Pancreatectomy for the Management of Left-Sided Pancreatic Cancer 微创远端胰腺切除术治疗左侧胰腺癌
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.S17.003
Y. Kawabata, T. Nishi, Y. Tajima
Curative surgical resection is considered the most effective treatment option to achieve long–term survival in patients with pancreatic cancer. In performing a Distal Pancreatectomy (DP) for left–sided pancreatic cancer, there are two main approaches to dissection: proceeding from left to right and from right to left. The conventional DP procedure was the Standard Retrograde Pancreatosplenectomy (SRPS), with a left–to–right dissection, and then the radical antegrade Modular Pancreatosplenectomy (RAMPS), with a right–to–left dissection, was developed. A greater number of harvested lymph nodes and an increase in R0 resection have been achieved in RAMPS as compared to SRPS; however, oncological outcomes, including patient survival, are comparable in these procedures. Recently, Minimally Invasive Distal Pancreatectomy (MIDP) using laparoscopy for pancreatic cancer has been advanced. The MIDP also has not been enough to show oncological benefits as compared with an open DP. Additional randomized controlled trials should be conducted to clarify the impacts and benefits of each surgical approach in performing DP for cancer of the body or tail of the pancreas
根治性手术切除被认为是实现胰腺癌患者长期生存的最有效的治疗选择。在对左侧胰腺癌进行远端胰腺切除术(DP)时,有两种主要的解剖方法:从左到右和从右到左。传统的DP手术是标准逆行胰脾切除术(SRPS),从左到右的夹层,然后是根治性顺行模块化胰脾切除术(RAMPS),从右到左的夹层。与SRPS相比,RAMPS获得了更多的淋巴结切除和R0切除;然而,肿瘤预后,包括患者生存,在这些手术中是相似的。近年来,腹腔镜下微创远端胰腺切除术(MIDP)治疗胰腺癌的研究取得了进展。与开放DP相比,MIDP也不足以显示肿瘤益处。应该进行额外的随机对照试验,以明确每种手术入路对身体或胰腺尾部癌症实施DP的影响和益处
{"title":"Minimally Invasive Distal Pancreatectomy for the Management of Left-Sided Pancreatic Cancer","authors":"Y. Kawabata, T. Nishi, Y. Tajima","doi":"10.35248/2157-2518.21.S17.003","DOIUrl":"https://doi.org/10.35248/2157-2518.21.S17.003","url":null,"abstract":"Curative surgical resection is considered the most effective treatment option to achieve long–term survival in patients with pancreatic cancer. In performing a Distal Pancreatectomy (DP) for left–sided pancreatic cancer, there are two main approaches to dissection: proceeding from left to right and from right to left. The conventional DP procedure was the Standard Retrograde Pancreatosplenectomy (SRPS), with a left–to–right dissection, and then the radical antegrade Modular Pancreatosplenectomy (RAMPS), with a right–to–left dissection, was developed. A greater number of harvested lymph nodes and an increase in R0 resection have been achieved in RAMPS as compared to SRPS; however, oncological outcomes, including patient survival, are comparable in these procedures. Recently, Minimally Invasive Distal Pancreatectomy (MIDP) using laparoscopy for pancreatic cancer has been advanced. The MIDP also has not been enough to show oncological benefits as compared with an open DP. Additional randomized controlled trials should be conducted to clarify the impacts and benefits of each surgical approach in performing DP for cancer of the body or tail of the pancreas","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"3 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72617942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Presentation of an Intertwined Tumor Chain from Diploid over Tetraploid towards the Aneuploid Tumors 从二倍体到四倍体到非整倍体肿瘤的缠绕肿瘤链的呈现
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.12.363
Rol, Sennerstam, Jan-Olov Strmberg, G. Auer
The role of Tetraploidization (TPZ) in tumor progression is not clearly described as an important link from one benign tumor to a more malign tumor. In this report we will intertwine the TPZ in a chain starting with diploid and during a lot of replicative stress parameters and hypoxia under increasing genomic instability losing genetic material and move down to aneuploids tumors. To arrange this connection between DNA (DI) entities we separated all tetraploid tumors in two subgroups (1.8 ≥ DI<2.0) and to (2.0 ≥ DI<2.2), and furthermore, two aneuploid groups divided in (1.2 ≥ DI<1.4) and (1.4 ≥ DI<1.8). This rather simple higher level of resolution has opened a new way to a deeper understanding of ploidy alterations during tumor progression. In total 1253 breast cancer patients divided in five decades were included from age <40 years and up to ≥ 70s. Two connected decades (50 ≥ age<70 years) were included in mammography screening interfering with the data and improved the results. The whole data of DNA- indices in each of the four DI intervals were included within (1.2 ≥ DI<2.2). Furthermore, the genomic instability was analyzed by three increasing levels of Stemline-Scatter Index (SSI): SSI<6, SSI<15 and SSI ≤ 60 rel. units which drives the genomic instability towards higher degree of malignancy.
四倍体化(TPZ)在肿瘤进展中的作用尚未被明确描述为从一个良性肿瘤到更恶性肿瘤的重要环节。在本报告中,我们将把TPZ缠绕在一条链上,从二倍体开始,在大量的复制应激参数和缺氧中,在基因组不稳定性增加的情况下,失去遗传物质并向下移动到非整倍体肿瘤。为了安排DNA (DI)实体之间的这种联系,我们将所有四倍体肿瘤分为两个亚组(1.8≥DI<2.0)和(2.0≥DI<2.2),此外,将两个非整倍体肿瘤分为(1.2≥DI<1.4)和(1.4≥DI<1.8)。这种相当简单的高分辨率为深入了解肿瘤进展过程中的倍性改变开辟了一条新途径。共有1253名乳腺癌患者在50年内被分为年龄<40岁至≥70岁。在乳房x光筛查中纳入两个相互关联的年代(50≥年龄<70岁),干扰了数据并改善了结果。4个DI区间DNA-指数的全部数据均纳入(1.2≥DI<2.2)。此外,基因组不稳定性通过3个升高水平(SSI <6, SSI<15和SSI≤60 rel. units)进行分析,SSI导致基因组不稳定性向更高程度的恶性肿瘤发展。
{"title":"Presentation of an Intertwined Tumor Chain from Diploid over Tetraploid towards the Aneuploid Tumors","authors":"Rol, Sennerstam, Jan-Olov Strmberg, G. Auer","doi":"10.35248/2157-2518.21.12.363","DOIUrl":"https://doi.org/10.35248/2157-2518.21.12.363","url":null,"abstract":"The role of Tetraploidization (TPZ) in tumor progression is not clearly described as an important link from one benign tumor to a more malign tumor. In this report we will intertwine the TPZ in a chain starting with diploid and during a lot of replicative stress parameters and hypoxia under increasing genomic instability losing genetic material and move down to aneuploids tumors. To arrange this connection between DNA (DI) entities we separated all tetraploid tumors in two subgroups (1.8 ≥ DI<2.0) and to (2.0 ≥ DI<2.2), and furthermore, two aneuploid groups divided in (1.2 ≥ DI<1.4) and (1.4 ≥ DI<1.8). This rather simple higher level of resolution has opened a new way to a deeper understanding of ploidy alterations during tumor progression. In total 1253 breast cancer patients divided in five decades were included from age <40 years and up to ≥ 70s. Two connected decades (50 ≥ age<70 years) were included in mammography screening interfering with the data and improved the results. The whole data of DNA- indices in each of the four DI intervals were included within (1.2 ≥ DI<2.2). Furthermore, the genomic instability was analyzed by three increasing levels of Stemline-Scatter Index (SSI): SSI<6, SSI<15 and SSI ≤ 60 rel. units which drives the genomic instability towards higher degree of malignancy.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"2 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78779054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statistics of Breast Cancer across Various Countries 各国乳腺癌统计数据
Pub Date : 2021-01-01 DOI: 10.35248/2157-2518.21.S18.001
Maegan A. Smith
{"title":"Statistics of Breast Cancer across Various Countries","authors":"Maegan A. Smith","doi":"10.35248/2157-2518.21.S18.001","DOIUrl":"https://doi.org/10.35248/2157-2518.21.S18.001","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"149 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75666764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of carcinogenesis & mutagenesis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1